- Home
- SAVA vs RENB Comparison
SAVA vs RENB Comparison
Compare SAVA & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- RENB
- Stock Information
- Founded
- SAVA 1998
- RENB 2011
- Country
- SAVA United States
- RENB United States
- Employees
- SAVA N/A
- RENB N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- RENB Health Care
- Exchange
- SAVA Nasdaq
- RENB Nasdaq
- Market Cap
- SAVA 70.5M
- RENB 62.0M
- IPO Year
- SAVA N/A
- RENB N/A
- Fundamental
- Price
- SAVA $1.99
- RENB $0.28
- Analyst Decision
- SAVA Buy
- RENB
- Analyst Count
- SAVA 3
- RENB 0
- Target Price
- SAVA $54.50
- RENB N/A
- AVG Volume (30 Days)
- SAVA 1.1M
- RENB 8.2M
- Earning Date
- SAVA 08-07-2025
- RENB 05-15-2025
- Dividend Yield
- SAVA N/A
- RENB N/A
- EPS Growth
- SAVA N/A
- RENB N/A
- EPS
- SAVA N/A
- RENB N/A
- Revenue
- SAVA N/A
- RENB N/A
- Revenue This Year
- SAVA N/A
- RENB N/A
- Revenue Next Year
- SAVA N/A
- RENB N/A
- P/E Ratio
- SAVA N/A
- RENB N/A
- Revenue Growth
- SAVA N/A
- RENB N/A
- 52 Week Low
- SAVA $1.15
- RENB $0.27
- 52 Week High
- SAVA $42.20
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- SAVA 51.90
- RENB 38.52
- Support Level
- SAVA $1.76
- RENB $0.33
- Resistance Level
- SAVA $2.17
- RENB $0.37
- Average True Range (ATR)
- SAVA 0.10
- RENB 0.04
- MACD
- SAVA -0.02
- RENB -0.01
- Stochastic Oscillator
- SAVA 55.95
- RENB 6.78
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.